These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33386676)

  • 1. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD.
    Kimura T; Tanaka N; Fujimori N; Yamazaki T; Katsuyama T; Iwashita Y; Pham J; Joshita S; Pydi SP; Umemura T
    Liver Int; 2021 Mar; 41(3):505-514. PubMed ID: 33386676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
    Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients.
    Iwadare T; Kimura T; Tanaka N; Yamazaki T; Wakabayashi SI; Okumura T; Kobayashi H; Yamashita Y; Pydi SP; Nakajima T; Iwaya M; Sugiura A; Joshita S; Uehara T; Umemura T
    Sci Rep; 2022 Nov; 12(1):18900. PubMed ID: 36344733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes.
    Lee CH; Seto WK; Lui DT; Fong CH; Wan HY; Cheung CY; Chow WS; Woo YC; Yuen MF; Xu A; Lam KS
    Diabetes Care; 2021 Sep; 44(9):2089-2097. PubMed ID: 34183428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
    Fujimori N; Umemura T; Kimura T; Tanaka N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Usami Y; Sano K; Igarashi K; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Mar; 24(11):1239-1249. PubMed ID: 29568204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
    Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease.
    Kimura T; Iwadare T; Wakabayashi SI; Kuldeep S; Nakajima T; Yamazaki T; Aomura D; Zafar H; Iwaya M; Joshita S; Uehara T; Pydi SP; Tanaka N; Umemura T
    Liver Int; 2024 Feb; 44(2):483-496. PubMed ID: 38010940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease.
    Wu X; Cheung CKY; Ye D; Chakrabarti S; Mahajan H; Yan S; Song E; Yang W; Lee CH; Lam KSL; Wang C; Xu A
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3230-e3240. PubMed ID: 35532410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
    Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
    Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
    Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
    AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
    Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.